Alexis Mosca

Alexis Mosca

Auto-generated profile, based on publicly available information

Alexis Mosca

Department of Pediatric Gastroenterology and Nutrition Robert‐Debré Hospital, APHP Paris France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2016 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
AMAlexis Mosca
Alexis Mosca
MLMarion Leclerc
Marion Leclerc
JHJean P. Hugot
Jean P. Hugot
Most of the Human diseases affecting westernized countries are associated with dysbiosis and loss of microbial diversity in the gut microbiota. The Western way of life, with a wide use of antibiotics and other environmental triggers, may reduce the number of bacterial predators leading to a decrease in microbial diversity of the Human gut. We argue that this phenomenon is similar to the process of ecosystem impoverishment in macro ecology where human activity decreases ecological niches, the size of predator populations and finally the biodiversity. Such pauperization is fundamental since it reverses the evolution processes, drives life backward into diminished complexity, stability and adaptability. A simple therapeutic approach could thus be to reintroduce bacterial predators and restore a bacterial diversity of the host microbiota.

1 January 2016 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
KMKaren Milcent
Karen Milcent
SFSabine Faesch
Sabine Faesch
CGChristèle Gras-Le Guen
Christèle Gras-Le Guen
FDFrançois Dubos
François Dubos
CPClaire Poulalhon
Claire Poulalhon
VGVincent Gajdos
Vincent Gajdos
The prevalence of severe bacterial infections (SBIs), defined as urinary tract infection (UTI), bacterial gastroenteritis, and more invasive bacterial infections (IBIs), such as bacteremia and meningitis, varies from 5% to 15% in infants younger than 3 months, and diagnostically reliable symptoms or clinical signs are few.1-5 Therefore, it can be difficult to distinguish young infants with SBIs from those with viral infection. As a result, a complete sepsis evaluation, empirical antibiotic therapy, and hospital admission are recommended for febrile infants up to 1 month of age and are common for those 1 to 2 months of age.1,2,4,6 Clinicobiological scores to identify patients at low risk of SBI have been developed to allow optimal treatment.1,6-8 These scores are less accurate in infants younger than 1 month,9-11 difficult to use in practice,12 and variably applied by physicians.3,12-15 Their cost and the associated iatrogenic morbidity have not been extensively evaluated. Management of such cases could be improved by new tools, and candidates include diagnostic tests for viral infection9,16 and procalcitonin (PCT) assays with earlier detection than usual biomarkers. The value of the PCT assay has been evaluated for the detection of SBI in infants17-22 and more specifically of IBI,23-25 and the findings are favorable. However, to our knowledge, few studies26-29 have assessed the performance of PCT assays for infants up to 3 months of age. The objective of this prospective study was to assess the diagnostic accuracy of PCT assays and to compare it with other, routinely used biomarkers for detecting SBI and IBI in febrile infants aged 7 to 91 days and for subgroups of infants according to their age (7-30 days or >30 days) and the duration of fever (≤6 hours).

2 October 2022 in Gut Microbes
Verified
Journal Article
Open access
AMAlexis Mosca
Alexis Mosca
AAAna Teresa Abreu Y Abreu
Ana Teresa Abreu Y Abreu
Kok Ann GweeKok Ann Gwee
Kok Ann Gwee
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
JTJan Tack
Jan Tack
CHColin Hill
Colin Hill
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy.

1 January 2006 in Clinical Immunology
Verified
Journal Article
Closed access
SCSophie Candon
Sophie Candon
AMAlexis Mosca
Alexis Mosca
FRFrank Ruemmele
Frank Ruemmele
OGOlivier Goulet
Olivier Goulet
LCLucienne Chatenoud
Lucienne Chatenoud
JCJean-Pierre Cézard
Jean-Pierre Cézard

1 March 2016 in Digestive and Liver Disease
Verified
Journal Article
Closed access
HSHarry Sokol
Harry Sokol
TGTatiana katerina Galpérine
Tatiana katerina Galpérine
NKNathalie Kapel
Nathalie Kapel
PBPierre Bourlioux
Pierre Bourlioux
PSPhilippe SEKSIK
Philippe SEKSIK
FZFrank Zerbib
Frank Zerbib

6 March 2007 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SLS. Leroy
S. Leroy
AMA. Mosca
A. Mosca
CLC. Landre-Peigne
C. Landre-Peigne
MCM.-A. Cosson
M.-A. Cosson
GPG. Pons
G. Pons